Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Arvinas presents preclinical data on BCL6 degrader ARV-393 in lymphoma

By Public Technologies
  • Arvinas’ VEPPANU (vepdegestrant) received FDA approval on May 1, 2026, becoming the first approved PROTAC protein degrader.
  • Rigel licensed VEPPANU in May 2026; commercial availability began in August 2026, with potential milestone payments and tiered royalties.
  • Cash runway extends into the second half of 2028; clinical-stage partnerships with Pfizer and Novartis generated more than $800 million.
  • Novartis is evaluating luxdegalutamide in three Phase 2 combination trials under a licensing deal potentially worth more than $1 billion.
  • ARV-393’s Phase 1 trial is enrolling lymphoma patients for monotherapy treatment or combination treatment with glofitamab.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.